MiMedx Group Q2 2026 Earnings Report

MiMedx Group EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.03
• Beat/Miss: N/A
• One Year Ago EPS: N/A

MiMedx Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $63.45 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

MiMedx Group Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: After Market Closes
• Conference Call Date: Wednesday, July 29, 2026
• Conference Call Time: 4:30PM ET

MiMedx Group (NASDAQ:MDXG). is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair. The company also supplies specialized bioimplants for orthopedic and spine procedures, supporting soft-tissue repair through its PURION® Plus technology platform. These products are used by wound care centers, hospitals, long-term care facilities and physician offices.

Headquartered in Marietta, Georgia, MiMedx serves a primarily U.S. customer base, with a growing international presence through distributors and strategic partnerships in Europe, Asia and Latin America. The company’s direct sales force works alongside a network of third-party distributors to educate clinicians on the clinical and economic benefits of its regenerative therapies. MiMedx continues to invest in clinical research and educational programs to expand awareness of placental-derived tissue allografts across multiple therapeutic areas.

Founded in 2008, MiMedx has grown from a niche tissue processor to an established player in the regenerative medicine sector. Over its history, the company has received approvals from the U.S. Food and Drug Administration for tissue donor eligibility and manufacturing practices governed by FDA and American Association of Tissue Banks (AATB) standards. Leadership includes experienced professionals in biotechnology and medical device commercialization, supported by a board with backgrounds in healthcare investment and corporate governance.